Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1223–1249 (2020).
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021).
Gabery, S. et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5, e133429 (2020).
Baraboi, E.-D., Smith, P., Ferguson, A. V. & Richard, D. Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1098–R1110 (2010).
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J. & Hayes, M. R. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152, 3103–3112 (2011).
Sisley, S. et al. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J. Clin. Invest. 124, 2456–2463 (2014).
Secher, A. et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Invest. 124, 4473–4488 (2014).
Hansen, H. H. et al. Whole-brain activation signatures of weight-lowering drugs. Mol. Metab. 47, 101171 (2021).
Carter, M. E., Soden, M. E., Zweifel, L. S. & Palmiter, R. D. Genetic identification of a neural circuit that suppresses appetite. Nature 503, 111–114 (2013).
Roman, C. W., Derkach, V. A. & Palmiter, R. D. Genetically and functionally defined NTS to PBN brain circuits mediating anorexia. Nat. Commun. 7, 11905 (2016).
Campos, C. A., Bowen, A. J., Schwartz, M. W. & Palmiter, R. D. Parabrachial CGRP neurons control meal termination. Cell Metab. 23, 811–820 (2016).
Huang, K.-P. et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature 632, 585–593 (2024).
Wilding, J. P. H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes. Metab. 24, 1553–1564 (2022).
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K. & Frühbeck, G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet 401, 1116–1130 (2023).
Garvey, W. T. et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat. Med. 28, 2083–2091 (2022).
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L. & Habener, J. F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl Acad. Sci. USA 84, 3434–3438 (1987).
Turton, M. D. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69–72 (1996).
Zhang, C. et al. Area postrema cell types that mediate nausea-associated behaviors. Neuron 109, 461–472 (2021).
Hayes, M. R. et al. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab. 13, 320–330 (2011).
Schwartz, J. H. The many dimensions of cAMP signaling. Proc. Natl Acad. Sci. USA 98, 13482–13484 (2001).
Musheshe, N., Schmidt, M. & Zaccolo, M. cAMP: from long-range second messenger to nanodomain signalling. Trends Pharmacol. Sci. 39, 209–222 (2018).
Chen, M. et al. Alternative Gnas gene products have opposite effects on glucose and lipid metabolism. Proc. Natl Acad. Sci. USA 102, 7386–7391 (2005).
Savani, R. et al. Metabolic and behavioral alterations associated with viral vector-mediated toxicity in the paraventricular hypothalamic nucleus. Biosci. Rep. 44, BSR20231846 (2024).
Orskov, C., Poulsen, S. S., Møller, M. & Holst, J. J. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45, 832–835 (1996).
Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131–2157 (2007).
Doyle, M. E. & Egan, J. M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 113, 546–593 (2007).
McNeill, S. M. et al. The role of G protein-coupled receptor kinases in GLP-1R β-arrestin recruitment and internalisation. Biochem. Pharmacol. 222, 116119 (2024).
Roed, S. N. et al. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol. Cell. Endocrinol. 382, 938–949 (2014).
Fletcher, M. M. et al. Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists. Biochem. Pharmacol. 156, 406–419 (2018).
Göke, R. et al. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 268, 19650–19655 (1993).
Liu, K. K.-C., Sakya, S. M., O’Donnell, C. J., Flick, A. C. & Ding, H. X. Synthetic approaches to the 2010 new drugs. Bioorg. Med. Chem. 20, 1155–1174 (2012).
Baumer-Harrison, C. et al. GLP-1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models. Diabetes Obes. Metab. 28, 2317–2328 (2026).
Douros, J. D. et al. A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice. Mol. Metab. 100, 102124 (2025).
Jones, B. The therapeutic potential of GLP-1 receptor biased agonism. Br. J. Pharmacol. 179, 492–510 (2022).
Möllmann, J. et al. The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. Diabetes Obes. Metab. 19, 496–508 (2017).
Gyldenløve, M. et al. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis—results from a randomized controlled trial (PSORRO). J. Am. Acad. Dermatol. 91, 64–71 (2024).
Hofer, A. M. & Lefkimmiatis, K. Extracellular calcium and cAMP: second messengers as ‘third messengers’? Physiology (Bethesda) 22, 320–327 (2007).
Zhang, S. X. et al. Hypothalamic dopamine neurons motivate mating through persistent cAMP signalling. Nature 597, 245–249 (2021).
Carter, M. E., Han, S. & Palmiter, R. D. Parabrachial calcitonin gene-related peptide neurons mediate conditioned taste aversion. J. Neurosci. 35, 4582–4586 (2015).
DeNardo, L. A. et al. Temporal evolution of cortical ensembles promoting remote memory retrieval. Nat. Neurosci. 22, 460–469 (2019).
Dong, Y. et al. Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo. Mol. Metab. 54, 101352 (2021).
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P. & Zdravkovic, M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45, 195–202 (2002).
Dong, S., Gu, Y., Wei, G., Si, D. & Liu, C. Determination of liraglutide in rat plasma by a selective liquid chromatography–tandem mass spectrometry method: application to a pharmacokinetics study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1091, 29–35 (2018).
Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C. & Hayes, M. R. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 62, 1916–1927 (2012).
Filippatos, T. D., Panagiotopoulou, T. V. & Elisaf, M. S. Adverse effects of GLP-1 receptor agonists. Rev. Diabet. Stud. 11, 202–230 (2014).
Brands, J. et al. A molecular mechanism to diversify Ca2+ signaling downstream of Gs protein-coupled receptors. Nat. Commun. 15, 7684 (2024).
Gupte, T. M., Malik, R. U., Sommese, R. F., Ritt, M. & Sivaramakrishnan, S. Priming GPCR signaling through the synergistic effect of two G proteins. Proc. Natl Acad. Sci. USA 114, 3756–3761 (2017).
Gupte, T. M., Ritt, M., Dysthe, M., Malik, R. U. & Sivaramakrishnan, S. Minute-scale persistence of a GPCR conformation state triggered by non-cognate G protein interactions primes signaling. Nat. Commun. 10, 4836 (2019).
Yacawych, W. T. et al. A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists. Preprint at bioRxiv https://doi.org/10.1101/2025.01.21.634167 (2025).
Blouet, C. & Schwartz, G. J. Brainstem nutrient sensing in the nucleus of the solitary tract inhibits feeding. Cell Metab. 16, 579–587 (2012).
Grill, H. J. & Hayes, M. R. The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake. Int. J. Obes. (Lond.) 33, S11–S15 (2009).
Tsang, A. H., Nuzzaci, D., Darwish, T., Samudrala, H. & Blouet, C. Nutrient sensing in the nucleus of the solitary tract mediates non-aversive suppression of feeding via inhibition of AgRP neurons. Mol. Metab. 42, 101070 (2020).
Grill, H. J. & Hayes, M. R. Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance. Cell Metab. 16, 296–309 (2012).
Ly, T. et al. Sequential appetite suppression by oral and visceral feedback to the brainstem. Nature 624, 130–137 (2023).
D’Agostino, G. et al. Appetite controlled by a cholecystokinin nucleus of the solitary tract to hypothalamus neurocircuit. eLife 5, e12225 (2016).
Roman, C. W., Sloat, S. R. & Palmiter, R. D. A tale of two circuits: CCKNTS neuron stimulation controls appetite and induces opposing motivational states by projections to distinct brain regions. Neuroscience 358, 316–324 (2017).
Aklan, I. et al. NTS catecholamine neurons mediate hypoglycemic hunger via medial hypothalamic feeding pathways. Cell Metab. 31, 313–326 (2020).
Sloop, K. W. et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci. Transl. Med. 16, eadp5765 (2024).
Oduori, O. S. et al. Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes. J. Clin. Invest. 130, 6639–6655 (2020).
Montrose-Rafizadeh, C. et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140, 1132–1140 (1999).
Koole, C. et al. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. J. Biol. Chem. 287, 3659–3673 (2012).
Wainger, B. J., DeGennaro, M., Santoro, B., Siegelbaum, S. A. & Tibbs, G. R. Molecular mechanism of cAMP modulation of HCN pacemaker channels. Nature 411, 805–810 (2001).
Porro, A. et al. The HCN domain couples voltage gating and cAMP response in hyperpolarization-activated cyclic nucleotide-gated channels. eLife 8, e49672 (2019).
Shinpo, K., Hirai, Y., Maezawa, H., Totsuka, Y. & Funahashi, M. The role of area postrema neurons expressing H-channels in the induction mechanism of nausea and vomiting. Physiol. Behav. 107, 98–103 (2012).
Weis, W. I. & Kobilka, B. K. The molecular basis of G protein-coupled receptor activation. Annu. Rev. Biochem. 87, 897–919 (2018).
Kawabe, J. et al. Differential activation of adenylyl cyclase by protein kinase C isoenzymes. J. Biol. Chem. 269, 16554–16558 (1994).
Wootten, D. et al. The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism. Cell 165, 1632–1643 (2016).
Kenakin, T. & Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205–216 (2013).
Wootten, D. et al. Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. Mol. Pharmacol. 83, 822–834 (2013).
Teixidor-Deulofeu, J. et al. Semaglutide effects on energy balance are mediated by Adcyap1+ neurons in the dorsal vagal complex. Cell Metab. 37, 1530–1546 (2025).
Ran, C., Boettcher, J. C., Kaye, J. A., Gallori, C. E. & Liberles, S. D. A brainstem map for visceral sensations. Nature 609, 320–326 (2022).
Heppner, K. M. et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 156, 255–267 (2015).
Merchenthaler, I., Lane, M. & Shughrue, P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403, 261–280 (1999).
Marassi, M. et al. Sex differences in the weight response to GLP-1RA in people with type 2 diabetes. A long-term longitudinal real-world study. Pharmacol. Res. 219, 107866 (2025).
Ghitani, N. et al. A distributed coding logic for thermosensation and inflammatory pain. Nature 642, 1016–1023 (2025).
de Araujo Salgado, I. et al. Toggling between food-seeking and self-preservation behaviors via hypothalamic response networks. Neuron 111, 2899–2917 (2023).
Joshi, K., Kirby, A., Niu, J. & VanderHorst, V. Stereotaxic surgical approach to microinject the caudal brainstem and upper cervical spinal cord via the cisterna magna in mice. J. Vis. Exp. https://doi.org/10.3791/63344 (2022).
Erben, L. & Buonanno, A. Detection and quantification of multiple RNA sequences using emerging ultrasensitive fluorescent in situ hybridization techniques. Curr. Protoc. Neurosci. 87, e63 (2019).
Alvarado, J. S. et al. Transient cAMP production drives rapid and sustained spiking in brainstem parabrachial neurons to suppress feeding. Neuron 112, 1416–1425 (2024).
Flotho, P., Nomura, S., Kuhn, B. & Strauss, D. J. Software for non-parametric image registration of 2-photon imaging data. J. Biophotonics 15, e202100330 (2022).
Pachitariu, M. & Stringer, C. Cellpose 2.0: how to train your own model. Nat. Methods 19, 1634–1641 (2022).
Guenthner, C. J., Miyamichi, K., Yang, H. H., Heller, H. C. & Luo, L. Permanent genetic access to transiently active neurons via TRAP: targeted recombination in active populations. Neuron 78, 773–784 (2013).
